Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med/AstraZeneca Drug Shows Efficacy Against Lung Cancer

publication date: Oct 17, 2017

Chi-Med (Hutchison China MediTech) and AstraZeneca presented positive safety and efficacy data of their partnered drug, the c-MET inhibitor savolitinib. Savolitinib was administered together with one of two AstraZeneca drugs -- Tagrisso^® (osimertinib) or Iressa^® (gefitinib) -- in two Phase Ib/II proof-of-concept trials in patients with non-small cell lung cancer. The patients had failed an earlier first-line treatment with an EGFR inhibitor. The most advanced savolitinib study is a recently started Phase III trial as a first-line treatment in patients with papillary renal cell carcinoma. More details....

Stock Symbols: (AIM/NSDQ: HCM) (NYSE: AZN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.